• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝炎的病理诊断标准:方案间一致性和预测肝相关死亡率的能力。

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.

机构信息

Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA.

出版信息

Hepatology. 2011 Jun;53(6):1874-82. doi: 10.1002/hep.24268. Epub 2011 May 14.

DOI:10.1002/hep.24268
PMID:21360720
Abstract

UNLABELLED

Since the initial description of nonalcoholic steatohepatitis (NASH), several sets of pathologic criteria for its diagnosis have been proposed. However, their interprotocol agreement and ability to predict long-term liver-related mortality (LRM) have not been demonstrated. In this study, we examined patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) for whom liver biopsy slides and clinical and mortality data were available. Liver biopsy samples were evaluated for a number of pathologic features and were classified according to the presence or absence of NASH by (1) the original criteria for NAFLD subtypes, (2) the nonalcoholic fatty liver disease activity score (NAS), (3) the Brunt criteria, and (4) the current study's criteria. All NASH diagnostic criteria and individual pathologic features were tested for agreement and for their independent associations with LRM, which were determined with a Cox proportional hazards model. Two hundred fifty-seven NAFLD patients with complete data were included. The diagnoses of NASH by the original NAFLD subtypes and by the current study's definition of NASH were in almost perfect agreement (κ = 0.896). However, their agreement was moderate with NAS (κ = 0.470 and κ = 0.511, respectively) and only fair to moderate with the Brunt criteria (κ = 0.365 and κ = 0.441, respectively). Furthermore, the agreement of the Brunt criteria with NAS was relatively poor (κ = 0.178). During the follow-up (median = 146 months), 31% of the patients died (9% were LRM). After we controlled for confounders, a diagnosis of NASH by the original criteria for NAFLD subtypes [adjusted hazard ratio = 9.94 (95% confidence interval = 1.28-77.08)] demonstrated the best independent association with LRM. Among the individual pathologic features, advanced fibrosis showed the best independent association with LRM [adjusted hazard ratio = 5.68 (95% confidence interval = 1.50-21.45)].

CONCLUSION

The original criteria for NAFLD subtypes and the current study's criteria for NASH were in almost perfect agreement, but their level of agreement with the NAS and Brunt criteria was lower. A diagnosis of NASH by the original criteria for NAFLD subtypes demonstrated the best predictability for LRM in NAFLD patients.

摘要

背景

自非酒精性脂肪性肝炎(NASH)最初描述以来,已经提出了几套用于其诊断的病理标准。然而,它们之间的协议和预测长期与肝脏相关死亡率(LRM)的能力尚未得到证实。在这项研究中,我们检查了经活检证实的非酒精性脂肪性肝病(NAFLD)患者,这些患者的肝活检切片和临床及死亡率数据可用。根据存在或不存在 NASH,对肝活检样本进行了多种病理特征的评估,并根据(1)NAFLD 亚型的原始标准,(2)非酒精性脂肪性肝病活动评分(NAS),(3)Brunt 标准和(4)本研究的标准进行分类。所有 NASH 诊断标准和各个病理特征均进行了一致性测试,并通过 Cox 比例风险模型确定了它们与 LRM 的独立关联。纳入了 257 例具有完整数据的 NAFLD 患者。根据原始的 NAFLD 亚型和本研究中 NASH 的定义,NASH 的诊断几乎完全一致(κ = 0.896)。但是,它们与 NAS 的一致性中等(κ = 0.470 和 κ = 0.511),与 Brunt 标准的一致性仅为中等(κ = 0.365 和 κ = 0.441)。此外,Brunt 标准与 NAS 的一致性相对较差(κ = 0.178)。在随访期间(中位数 = 146 个月),31%的患者死亡(9%为 LRM)。在控制混杂因素后,NAFLD 亚型的原始标准诊断为 NASH [校正后的危险比= 9.94(95%置信区间= 1.28-77.08)],与 LRM 的相关性最好。在各个病理特征中,晚期纤维化与 LRM 的相关性最好[校正后的危险比= 5.68(95%置信区间= 1.50-21.45)]。

结论

NAFLD 亚型的原始标准和本研究中 NASH 的标准几乎完全一致,但它们与 NAS 和 Brunt 标准的一致性较低。NAFLD 患者中,NAFLD 亚型的原始标准诊断为 NASH,对 LRM 的预测性最佳。

相似文献

1
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.非酒精性脂肪性肝炎的病理诊断标准:方案间一致性和预测肝相关死亡率的能力。
Hepatology. 2011 Jun;53(6):1874-82. doi: 10.1002/hep.24268. Epub 2011 May 14.
2
Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.非酒精性脂肪性肝病活动评分(NAS)在预测纤维化进展方面的临床相关性较低。
Scand J Gastroenterol. 2012 Jan;47(1):108-15. doi: 10.3109/00365521.2011.634024. Epub 2011 Nov 30.
3
Validation of the non-alcoholic fatty liver disease activity score.非酒精性脂肪性肝病活动评分的验证。
Aliment Pharmacol Ther. 2011 Jul;34(2):214-8. doi: 10.1111/j.1365-2036.2011.04695.x. Epub 2011 May 18.
4
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease.疑似非酒精性脂肪性肝病的病态肥胖患者配对肝活检的相关性
Hepatology. 2006 Oct;44(4):874-80. doi: 10.1002/hep.21346.
5
Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.2 型糖尿病患者非酒精性脂肪性肝病的组织病理学分期:患病率及相关因素。
Liver Int. 2011 May;31(5):700-6. doi: 10.1111/j.1478-3231.2011.02482.x. Epub 2011 Feb 20.
6
[Role of liver biopsy in the diagnosis of NASH].[肝活检在非酒精性脂肪性肝炎诊断中的作用]
Nihon Rinsho. 2006 Jun;64(6):1119-25.
7
Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease.中性粒细胞与淋巴细胞比值:预测非酒精性脂肪性肝病患者脂肪性肝炎和纤维化的新标志物。
Liver Int. 2012 Feb;32(2):297-302. doi: 10.1111/j.1478-3231.2011.02639.x. Epub 2011 Sep 8.
8
[Clinical and histological features of non-alcoholic fatty liver disease].非酒精性脂肪性肝病的临床和组织学特征
Zhonghua Gan Zang Bing Za Zhi. 2009 Nov;17(11):812-6.
9
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.病态肥胖患者非酒精性脂肪性肝炎和肝纤维化进展的预测因素
Obes Surg. 2005 Mar;15(3):310-5. doi: 10.1381/0960892053576820.
10
Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.非酒精性脂肪性肝病/非酒精性脂肪性肝炎:组织学诊断标准及评分系统。
Eur J Gastroenterol Hepatol. 2010 Jun;22(6):643-50. doi: 10.1097/MEG.0b013e32832ca0cb.

引用本文的文献

1
The application of EUS-guided portal pressure gradient measurement with concomitant EUS-liver elastography and EUS-guided liver biopsy in patients with chronic liver disease: a single center experience.内镜超声引导下门静脉压力梯度测量联合内镜超声引导下肝脏弹性成像及内镜超声引导下肝活检在慢性肝病患者中的应用:单中心经验
Therap Adv Gastroenterol. 2025 Jul 30;18:17562848251359015. doi: 10.1177/17562848251359015. eCollection 2025.
2
Metabolite perturbations in type 1 diabetes associated with metabolic dysfunction-associated steatotic liver disease.1型糖尿病中与代谢功能障碍相关脂肪性肝病相关的代谢物扰动。
Front Endocrinol (Lausanne). 2025 Jun 3;16:1500242. doi: 10.3389/fendo.2025.1500242. eCollection 2025.
3
A Critical Role for the Mitochondrial Pyruvate Carrier in Hepatic Stellate Cell Activation.
线粒体丙酮酸载体在肝星状细胞激活中的关键作用
Cell Mol Gastroenterol Hepatol. 2025 Apr 14;19(8):101517. doi: 10.1016/j.jcmgh.2025.101517.
4
Clinical associations of portal-based disease in MASLD: proposal of a new histological scoring system.非酒精性脂肪性肝病门静脉相关疾病的临床关联:一种新的组织学评分系统的提议
Virchows Arch. 2025 Apr 10. doi: 10.1007/s00428-025-04087-5.
5
HEPNET Position Statement-I, Case Definition, Classification, Screening & Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Pakistan: A Resource for Primary and Secondary Care Physicians.巴基斯坦肝脏网络立场声明 - I,代谢功能障碍相关脂肪性肝病(MASLD)的病例定义、分类、筛查与诊断:基层和二级医疗医生资源
Pak J Med Sci. 2025 Mar;41(3):929-938. doi: 10.12669/pjms.41.3.10081.
6
Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study.以基于磁共振成像的质子密度脂肪分数为参考标准,比较衰减成像与受控衰减参数对肝脂肪变性的诊断性能:一项前瞻性多中心研究。
J Gastroenterol. 2025 Jun;60(6):727-737. doi: 10.1007/s00535-025-02224-0. Epub 2025 Feb 24.
7
Clinical Assessment of Common Medications for Nonalcoholic Fatty Liver Disease: A Systematic Review and Bayesian Network Meta-Analysis.非酒精性脂肪性肝病常用药物的临床评估:系统评价与贝叶斯网络Meta分析
J Evid Based Med. 2025 Mar;18(1):e70002. doi: 10.1111/jebm.70002.
8
Protective effects of against hepatocyte apoptosis and liver fibrosis induced by high palmitic acid diet.(此处原文不完整,缺少具体物质等关键信息,推测完整句子可能是“某物质对抗高棕榈酸饮食诱导的肝细胞凋亡和肝纤维化的保护作用” )针对高棕榈酸饮食诱导的肝细胞凋亡和肝纤维化的保护作用 (因原文关键部分缺失,此译文仅根据现有内容尽量贴合原意翻译)
Front Pharmacol. 2025 Jan 9;15:1438997. doi: 10.3389/fphar.2024.1438997. eCollection 2024.
9
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).代谢功能障碍相关脂肪性肝炎(MASH)的治疗前景
Nat Rev Drug Discov. 2025 Mar;24(3):171-189. doi: 10.1038/s41573-024-01084-2. Epub 2024 Nov 28.
10
Using Panel Management to Identify Adult Patients With High-Risk Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis Fibrosis in a Primary Care Clinic: A Pilot Study.在初级保健诊所中使用面板管理识别患有高危代谢功能障碍相关脂肪性肝病/代谢功能障碍相关脂肪性肝炎纤维化的成年患者:一项试点研究。
Perm J. 2024 Dec 16;28(4):38-47. doi: 10.7812/TPP/24.094. Epub 2024 Oct 24.